← back to search

Xin Han

Hebei Medical University · CN
🔎 Find collaborators in Hepatology · Oncology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Hepatology · Oncology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Inflammatory Biomarkers in Disease Prognosis, Cancer Mechanisms and Therapy, and Ferroptosis and cancer prognosis.
h-index
11
citations
308
works
26
NIH funding
primary concept
email

Recent publications

Identification and validation of a lenvatinib resistance-related prognostic signature in HCC, in which PFKFB4 contributes to tumor progression and lenvatinib resistance
BMC Gastroenterology 2025cited by 3position: middledoi
Comparative efficacy of interventional therapy with or without targeted immunotherapy in Child-Pugh B hepatocellular carcinoma patients: a single-center, retrospective study
Frontiers in Oncology 2025cited by 1position: middledoi
Notch1 signaling pathway contributes to sorafenib resistance in hepatocellular carcinoma by modulating the cell cycle, mitochondrial function, and epithelial–mesenchymal transition
Research Square 2024cited by 0position: middledoi
A model based on Immunogenic cell death-related genes can predict prognosis and drug sensitivity in patients with hepatocellular carcinoma
Research Square 2024cited by 0position: middledoi
Immune checkpoint inhibitors combined with targeted agents for the first-line treatment of advanced unresectable hepatocellular carcinoma: a systematic review and meta-analysis
2024cited by 0position: lastdoi
Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
Technology in Cancer Research & Treatment 2023cited by 13position: middledoi
Molecular typing and mutational characterization of rectal neuroendocrine neoplasms
Cancer Medicine 2023cited by 11position: middledoi
Matrine improves the hepatic microenvironment and reverses epithelial-mesenchymal transition in hepatocellular carcinoma by inhibiting the Wnt-1/β-catenin signaling pathway.
PubMed 2023cited by 4position: middle
Dicer Suppresses Hepatocellular Carcinoma via Interleukin-8 Pathway
Clinical Medicine Insights Oncology 2023cited by 2position: firstdoi
Sarcopenia and Systemic Inflammation Response Index Predict Response to Systemic Therapy for Hepatocellular Carcinoma and Are Associated With Immune Cells
Frontiers in Oncology 2022cited by 57position: middledoi
Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index
Future Oncology 2022cited by 30position: middledoi
Effects of TACE combined with sorafenib on survival of patients with hepatocellular carcinoma based on ALBI grades and tumor load layers And Establishment of prognosis prediction model
Research Square 2022cited by 0position: middledoi
Matrine promotes hepatic oval cells differentiation into hepatocytes and alleviates liver injury by suppression of Notch signalling pathway
Life Sciences 2020cited by 18position: middledoi
Circ_0000144 functions as a miR-623 sponge to enhance gastric cancer progression via up-regulating GPRC5A
Bioscience Reports 2020cited by 8position: middledoi
Effects of tumor distance from anal verge on survival outcomes for rectal NENs and lymphatic metastasis risk score for colorectal NENs
International Journal of Colorectal Disease 2020cited by 7position: middledoi
<sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography Metabolic Parameters Before and After Neoadjuvant Chemotherapy Can Predict the Postoperative Prognosis of Locally Advanced Gastric Cancer
Cancer Biotherapy and Radiopharmaceuticals 2020cited by 3position: middledoi
Matrine prevents the early development of hepatocellular carcinoma like lesions in rat liver
Experimental and Therapeutic Medicine 2019cited by 17position: middledoi
Combined intra-arterial and intravenous chemotherapy for unresectable, advanced gastric cancer has an improved curative effect compared with intravenous chemotherapy only
Oncology Letters 2018cited by 16position: middledoi
Importance of SALL4 in the development and prognosis of hepatocellular carcinoma
World Journal of Gastroenterology 2016cited by 45position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Fei Yin · Hebei Medical University19 papers (2016–2025)Jianfei Shi · Hebei Medical University18 papers (2018–2025)Lili Mi · Hebei Medical University16 papers (2018–2025)Man Zhao · Hebei Medical University16 papers (2018–2025)Xiaoling Duan · Hebei Medical University15 papers (2018–2025)Guangjie Han · Hebei Medical University13 papers (2018–2025)Jiaojiao Hou · Hebei Medical University6 papers (2022–2025)Cuizhen Li · Hebei Medical University4 papers (2019–2024)Jinfeng Wang · Hebei Medical University4 papers (2023–2025)Huacun Shi · Hebei Medical University3 papers (2018–2020)Ning Li · Hebei Medical University3 papers (2023–2025)Ning Li · The First Affiliated Hospital, Sun Yat-sen University3 papers (2020–2022)Jinsheng Xu · Hebei Medical University3 papers (2019–2020)Ning Li · Harbin Medical University2 papers (2020–2023)Ning Li · Central South University2 papers (2022–2023)Ning Li · China Earthquake Administration2 papers (2018–2019)Xiaonan Yin · Chinese Academy of Medical Sciences & Peking Union Medical College1 papers (2022–2022)Xiaoling Wang · Shanghai Jiao Tong University1 papers (2016–2016)Hua Zhang · Changzhou University1 papers (2023–2023) · 1 papers (2024–2024)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Hepatology · Oncology →